

Preclinical Alzheimer's disease and its outcome: a longit

Lancet Neurology, The

12, 957-965

DOI: [10.1016/s1474-4422\(13\)70194-7](https://doi.org/10.1016/s1474-4422(13)70194-7)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Frontiers for Collaborative Research. <i>Science Translational Medicine</i> , 2013, 5, 216ed22.	5.8	8
2	Do preclinical Alzheimer's disease criteria work?. <i>Lancet Neurology</i> , The, 2013, 12, 933-935.	4.9	7
3	Preclinical Alzheimer's disease criteria. <i>Lancet Neurology</i> , The, 2013, 12, 1134.	4.9	6
4	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. <i>Advances in Geriatrics</i> , 2014, 2014, 1-14.	1.6	15
5	Neuropathology of Dementia Disorders. , 2014, 04, .		10
6	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. <i>Neurology</i> , 2014, 83, 434-440.	1.5	61
7	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 534-543.	1.7	96
8	Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition. <i>Acta Neuropathologica Communications</i> , 2014, 2, 26.	2.4	77
9	PART and SNAP. <i>Acta Neuropathologica</i> , 2014, 128, 773-776.	3.9	78
10	Memory difficulties are not always a sign of incipient dementia: a review of the possible causes of loss of memory efficiency. <i>British Medical Bulletin</i> , 2014, 112, 71-81.	2.7	54
11	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid $\beta$ -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282.	4.5	300
12	Synergistic Effect of $\beta$ -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. <i>JAMA Neurology</i> , 2014, 71, 1379.	4.5	273
13	Mild Cognitive Impairment: A Concept and Diagnostic Entity in Need of Input from Neuropsychology. <i>Journal of the International Neuropsychological Society</i> , 2014, 20, 129-134.	1.2	79
14	Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span. <i>JAMA Neurology</i> , 2014, 71, 742.	4.5	40
15	Emerging $\beta$ -Amyloid Pathology and Accelerated Cortical Atrophy. <i>JAMA Neurology</i> , 2014, 71, 725.	4.5	51
16	Preventing cognitive decline in preclinical Alzheimer's disease. <i>Current Opinion in Pharmacology</i> , 2014, 14, 18-22.	1.7	21
17	Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. <i>Brain</i> , 2014, 137, 1762-1771.	3.7	234
18	Understanding the cause of sporadic Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 621-630.	1.4	47

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid $\beta$ -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	2.8	110
20	The landscape of ageing—insights from AD imaging markers. <i>Nature Reviews Neurology</i> , 2014, 10, 678-679.	4.9	11
21	Alzheimer-associated urine neuronal thread protein level increases with age in a healthy Chinese population. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 2118-2121.	0.8	12
22	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
23	Alzheimer's Preventive Approaches and Cognitive Monitoring Must Be Integrated Into the Primary Care Setting. <i>Journal of the American Medical Directors Association</i> , 2014, 15, 783-785.	1.2	0
24	Harmonized diagnostic criteria for Alzheimer's disease: recommendations. <i>Journal of Internal Medicine</i> , 2014, 275, 204-213.	2.7	101
25	Primary age-related tauopathy (PART): a common pathology associated with human aging. <i>Acta Neuropathologica</i> , 2014, 128, 755-766.	3.9	1,060
26	Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy. <i>Nature Reviews Neurology</i> , 2014, 10, 620-633.	4.9	258
27	The Role of Olfactory Challenge Tests in Incipient Dementia and Clinical Trial Design. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 479.	2.0	18
28	Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 338-348.	4.0	127
29	The 2013 SFRBM discovery award: Selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. <i>Free Radical Biology and Medicine</i> , 2014, 74, 157-174.	1.3	103
30	Age-specific population frequencies of cerebral $\beta$ -amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	4.9	297
31	The Relevance of Beta-Amyloid on Markers of Alzheimer's Disease in Clinically Normal Individuals and Factors That Influence These Associations. <i>Neuropsychology Review</i> , 2014, 24, 300-312.	2.5	34
32	The need for "objective measurements" in FDG and amyloid PET neuroimaging. <i>Clinical and Translational Imaging</i> , 2014, 2, 331-342.	1.1	4
33	Biochemical stages of amyloid- $\beta$ peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 887-903.	3.7	136
34	Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 275-289.	1.2	493
35	Smoking and increased Alzheimer's disease risk: A review of potential mechanisms. <i>Alzheimer's and Dementia</i> , 2014, 10, S122-45.	0.4	285
36	Spreading of Amyloid, Tau, and Microvascular Pathology in Alzheimer's Disease: Findings from Neuropathological and Neuroimaging Studies. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S421-S429.	1.2	75

#	ARTICLE	IF	CITATIONS
37	Biomarkers for Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1051-1069.	1.2	84
38	Strategic Opportunities in Sleep and Circadian Research: Report of the Joint Task Force of the Sleep Research Society and American Academy of Sleep Medicine. <i>Sleep</i> , 2014, 37, 219-227.	0.6	62
39	Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study. <i>Journal of the International Neuropsychological Society</i> , 2015, 21, 573-583.	1.2	29
40	CSF beta-amyloid 1-42: what are we measuring in Alzheimer's disease?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 131-139.	1.7	34
41	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 534-547.	1.7	32
42	Absence of practice effects in preclinical Alzheimer's disease. <i>Neuropsychology</i> , 2015, 29, 940-948.	1.0	98
43	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-2 Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	1.2	47
44	Targeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 793-813.	1.2	108
45	Mapping the Relationship of Contributing Factors for Preclinical Alzheimer's Disease. <i>Scientific Reports</i> , 2015, 5, 11259.	1.6	4
46	Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 231-242.	1.2	147
47	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	1.2	11
48	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 261-270.	1.2	14
49	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 403-411.	1.2	26
50	Diagnostic value of cerebrospinal fluid A $\beta$ ratios in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 75.	3.0	47
51	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 617-631.	1.2	330
53	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. <i>Frontiers in Neurology</i> , 2015, 6, 256.	1.1	16
54	Expression of Concern: Sato et al. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. <i>JAMA</i> . 2005;293(9):1082-1088.. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1914.	3.8	3
55	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. <i>Neuropsychologia</i> , 2015, 73, 169-175.	0.7	57

#	ARTICLE	IF	CITATIONS
56	Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. <i>Nature Neuroscience</i> , 2015, 18, 800-806.	7.1	582
57	Interview with Dr John Morris, 28 February 2013. <i>Dementia</i> , 2015, 14, 335-342.	1.0	0
58	The Structural and Functional Connectome and Prediction of Risk for Cognitive Impairment in Older Adults. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 234-245.	0.6	41
59	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 412-419.	1.2	80
60	Relationship between Cognitive Impairment and Echocardiographic Parameters: A Review. <i>Journal of the American Society of Echocardiography</i> , 2015, 28, 264-274.	1.2	14
61	Learning by Failing: Ideas and Concepts to Tackle $\beta$ -Secretases in Alzheimer's Disease and Beyond. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 419-437.	4.2	117
62	Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 511-522.	0.4	55
63	Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective. <i>Advances in Medical Sciences</i> , 2015, 60, 76-82.	0.9	56
64	The Na <sup>+</sup> /H <sup>+</sup> Exchanger NHE6 Modulates Endosomal pH to Control Processing of Amyloid Precursor Protein in a Cell Culture Model of Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2015, 290, 5311-5327.	1.6	55
65	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
66	Cognitive impairment, all-cause and cause-specific mortality among non-demented older adults. <i>Age and Ageing</i> , 2015, 44, 445-451.	0.7	90
67	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.4	142
68	Memory, executive, and multidomain subtle cognitive impairment. <i>Neurology</i> , 2015, 85, 144-153.	1.5	42
69	The role of positron emission tomography imaging in understanding Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 395-406.	1.4	27
70	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. <i>Clinical and Translational Imaging</i> , 2015, 3, 65-74.	1.1	7
71	Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 2.	3.0	19
72	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
73	Defining Amyloid Pathology in Persons With and Without Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1913.	3.8	9

#	ARTICLE	IF	CITATIONS
74	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
75	Plasma amyloid $\beta$ <sup>1-2</sup> and risk of Alzheimer's disease in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2015, 11, 249.	0.4	101
76	Mediterranean Diet and Age-Related Cognitive Decline. <i>JAMA Internal Medicine</i> , 2015, 175, 1094.	2.6	653
77	Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 699.	4.5	75
78	PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2015, 129, 757-762.	3.9	139
79	Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer's disease biomarkers. <i>Neurobiology of Aging</i> , 2015, 36, 1771-1779.	1.5	36
80	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 59.	3.0	101
81	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. <i>Brain</i> , 2015, 138, 3747-3759.	3.7	170
82	Cerebrospinal fluid A $\beta$ <sup>240</sup> is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. <i>Journal of the Neurological Sciences</i> , 2015, 358, 308-316.	0.3	25
83	Integrated multimodal imaging in neurodegenerative disease. <i>Lancet Neurology</i> , The, 2015, 14, 973-975.	4.9	3
84	Suspected non-AD pathology in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2015, 36, 3152-3162.	1.5	63
85	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
86	Neuropathology and biochemistry of A $\beta$ <sup>1-2</sup> and its aggregates in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2015, 129, 167-182.	3.9	224
87	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
88	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69.	0.4	352
89	APOE and BDNF polymorphisms moderate amyloid $\beta$ <sup>1-2</sup> -related cognitive decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2015, 20, 1322-1328.	4.1	105
90	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. <i>Alzheimer's and Dementia</i> , 2015, 11, 600.	0.4	656
91	The Aging Mind in Transition. , 2016, , 87-103.		3

#	ARTICLE	IF	CITATIONS
92	Neuropsychiatric Symptoms in Mild Cognitive Impairment as Risk Factors for Progression to Dementia. Journal of Neurology and Neuroscience, 2016, 06, .	0.4	1
93	Spatial Navigation in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 52, 77-90.	1.2	156
94	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. Journal of Alzheimer's Disease, 2016, 51, 227-236.	1.2	14
95	Spatial Patterns of Longitudinal Gray Matter Change as Predictors of Concurrent Cognitive Decline in Amyloid Positive Healthy Subjects. Journal of Alzheimer's Disease, 2016, 55, 343-358.	1.2	10
96	<scp>CSF sTREM</scp> 2: marking the tipping point between preclinical <scp>AD</scp> and dementia?. EMBO Molecular Medicine, 2016, 8, 437-438.	3.3	3
97	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. Journal of Alzheimer's Disease, 2016, 53, 1097-1105.	1.2	44
98	Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 1085-1097.	1.2	12
99	Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. Journal of the International Neuropsychological Society, 2016, 22, 968-977.	1.2	15
101	Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning. Neurobiology of Aging, 2016, 43, 23-33.	1.5	49
102	White matter hyperintensities are more highly associated with preclinical Alzheimer's disease than imaging and cognitive markers of neurodegeneration. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 18-27.	1.2	71
103	â€œNew Old Pathologiesâ€ AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). Journal of Neuropathology and Experimental Neurology, 2016, 75, 482-498.	0.9	130
104	Tau: From research to clinical development. Alzheimer's and Dementia, 2016, 12, 1033-1039.	0.4	117
105	Mild Cognitive Impairment in Late Middle Age in the Wisconsin Registry for Alzheimer's Prevention Study: Prevalence and Characteristics Using Robust and Standard Neuropsychological Normative Data. Archives of Clinical Neuropsychology, 2016, 31, 675-688.	0.3	48
106	Cerebrospinal fluid analysis detects cerebral amyloid- $\beta^2$ accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	3.7	292
107	Cognitive Decline in Preclinical Stage 2 Alzheimer Disease and Implications for Prevention Trials. JAMA Neurology, 2016, 73, 640.	4.5	5
108	NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiology of Aging, 2016, 44, 1-8.	1.5	80
109	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 82-92.	1.8	97
110	Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. JAMA Neurology, 2016, 73, 698.	4.5	94

#	ARTICLE	IF	CITATIONS
111	Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 1095-1104.	0.6	95
112	Cognitive and functional changes associated with A $\beta$ pathology and the progression to mild cognitive impairment. <i>Neurobiology of Aging</i> , 2016, 48, 172-181.	1.5	28
113	Parkinson disease and cognitive impairment. <i>Neurology: Clinical Practice</i> , 2016, 6, 452-458.	0.8	34
114	Nmnat1 protects neuronal function without altering phospho $\tau$ pathology in a mouse model of tauopathy. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 434-442.	1.7	23
115	Classifying anatomical subtypes of subjective memory impairment. <i>Neurobiology of Aging</i> , 2016, 48, 53-60.	1.5	23
116	Reference measurement procedure for $\text{CSF} \text{ amyloid beta (A}\beta\text{)}_{42}$ and the $\text{CSF} \text{ A}\beta_{42}/\text{A}\beta_{40}$ ratio – a cross-validation study against amyloid $\text{PET}$ . <i>Journal of Neurochemistry</i> , 2016, 139, 651-658.		78
117	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	4.5	52
118	Longitudinal $\beta$ -Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2016, 73, 1192.	4.5	77
119	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. <i>Lancet Neurology</i> , The, 2016, 15, 1044-1053.	4.9	175
120	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2016, 46, 32-42.	1.5	20
121	Genetic and degenerative disorders primarily causing dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 525-564.	1.0	5
122	Suspected non-Alzheimer disease pathophysiology – concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
123	Functional connectivity assessed by resting state EEG correlates with cognitive decline of Alzheimer's disease – An eLORETA study. <i>Clinical Neurophysiology</i> , 2016, 127, 1269-1278.	0.7	163
124	Alzheimer's disease biomarker states. <i>Lancet Neurology</i> , The, 2016, 15, 25-26.	4.9	3
125	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
126	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.4	42
127	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. <i>Neurological Sciences</i> , 2016, 37, 663-672.	0.9	52
128	Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 259-277.	1.4	35



#	ARTICLE	IF	CITATIONS
129	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
130	Alzheimer's disease. <i>Lancet</i> , The, 2016, 388, 505-517.	6.3	2,430
131	Braak stage and trajectory of cognitive decline in noncognitively impaired elders. <i>Neurobiology of Aging</i> , 2016, 43, 101-110.	1.5	28
132	Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 131, 235-246.	3.9	53
133	Is amyloid- $\beta^2$ harmful to the brain? Insights from human imaging studies. <i>Brain</i> , 2016, 139, 23-30.	3.7	87
134	Risk of dementia and death in the long-term follow-up of the Pittsburgh Cardiovascular Health Study's "Cognition Study. <i>Alzheimer's and Dementia</i> , 2016, 12, 170-183.	0.4	33
135	A sandwich immunoassay for detection of A $\beta^{1-42}$ based on quantum dots. <i>Talanta</i> , 2016, 146, 10-15.	2.9	26
136	Mapping CSF biomarker profiles onto NIA's AA guidelines for Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 587-597.	1.8	14
137	Amyloid imaging in cognitively normal older adults: comparison between 18F-flutemetamol and 11C-Pittsburgh compound B. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 142-151.	3.3	41
138	Amyloid- $\beta^2$ and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. <i>Molecular Psychiatry</i> , 2017, 22, 306-311.	4.1	105
139	Preclinical Alzheimer's disease and longitudinal driving decline. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 74-82.	1.8	44
140	Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. <i>Annals of Neurology</i> , 2017, 81, 549-559.	2.8	83
141	Future Directions in Imaging Neurodegeneration. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 9.	2.0	13
142	APOE $\epsilon^4$ Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 411-422.	1.2	9
143	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
144	Suspected non-Alzheimer's pathology " Is it non-Alzheimer's or non-amyloid?. <i>Ageing Research Reviews</i> , 2017, 36, 20-31.	5.0	34
145	Emerging biomarkers and screening for cognitive frailty. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	1.4	39
146	Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease. <i>Neurobiology of Aging</i> , 2017, 56, 25-32.	1.5	57

#	ARTICLE	IF	CITATIONS
147	Detectable Neuropsychological Differences in Early Preclinical Alzheimer's Disease: A Meta-Analysis. <i>Neuropsychology Review</i> , 2017, 27, 305-325.	2.5	76
148	Age-specific and sex-specific prevalence of cerebral $\beta$ -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
149	Circadian Rhythms in AD Pathogenesis: a Critical Appraisal. <i>Current Sleep Medicine Reports</i> , 2017, 3, 85-92.	0.7	26
150	Cerebrospinal Fluid Biomarkers and Clinical Progression in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 939-950.	1.2	74
151	Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2305.	3.8	311
152	Brain Amyloid Pathology and Cognitive Function. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2285.	3.8	15
153	Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project. <i>BMJ Open</i> , 2017, 7, e013215.	0.8	28
154	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189.	1.5	20
155	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 557.	4.5	664
156	Identifying memory impairment and early dementia in primary care. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 188-195.	1.2	13
157	Alzheimer Disease Signature Neurodegeneration and <i>APOE</i> Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2017, 74, 650.	4.5	24
158	Screening Younger Individuals in a Primary Care Setting Flags Putative Dementia Cases and Correlates Gastrointestinal Diseases with Poor Cognitive Performance. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 43, 15-28.	0.7	14
159	Combining Gait Speed and Recall Memory to Predict Survival in Late Life: Population-Based Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 614-618.	1.3	15
160	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.5	15
161	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1387-1395.	1.2	24
162	Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 439-446.	1.4	32
163	Assessment of amyloid $\beta$ in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	1.2	38
164	Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 509-513.	1.2	11

#	ARTICLE	IF	CITATIONS
165	Amyloid $\beta$ -associated cognitive decline in the absence of clinical disease progression and systemic illness. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 156-164.	1.2	19
166	Clinically silent Alzheimer's and vascular pathologies influence brain networks supporting executive function in healthy older adults. <i>Neurobiology of Aging</i> , 2017, 58, 102-111.	1.5	15
167	Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 747-762.	1.2	9
168	Predicting Regional Pattern of Longitudinal $\beta$ -Amyloid Accumulation by Baseline PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 639-645.	2.8	17
169	Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status. <i>Clinical Neuropsychologist</i> , 2017, 31, 99-117.	1.5	47
170	Microfinance literature: A sustainability level perspective survey. <i>Journal of Cleaner Production</i> , 2017, 142, 3382-3395.	4.6	38
171	$\beta$ -amyloid and Tau Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 75-88.	2.5	96
172	The DIAN Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. <i>Alzheimer's and Dementia</i> , 2017, 13, 8-19.	0.4	230
173	Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis. , 2017, , 17-26.		0
174	Ultra-Early Phase pathologies of Alzheimer's disease and other neurodegenerative diseases. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 361-377.	1.6	9
175	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 117.	1.7	71
176	Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid. <i>Frontiers in Neurology</i> , 2017, 8, 102.	1.1	92
177	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 281.	1.4	62
178	APOE allele frequencies in suspected non-amyloid pathophysiology (SNAP) and the prodromal stages of Alzheimer's Disease. <i>PLoS ONE</i> , 2017, 12, e0188501.	1.1	10
179	Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. <i>Molecular Neurodegeneration</i> , 2017, 12, 63.	4.4	202
180	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	3.0	316
181	Use of the Quick Dementia Rating System (QDRS) as an Initial Screening Measure in a Longitudinal Cohort at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 9-13.	1.2	23
182	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 757-771.	1.6	31

#	ARTICLE	IF	CITATIONS
183	Biomarkers for Preclinical Alzheimer's Disease. <i>NeuroMethods</i> , 2018, , .	0.2	5
184	Cognitive and neuroimaging features and brain $\beta$ -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	4.9	161
185	One step towards dementia prevention. <i>Lancet Neurology</i> , The, 2018, 17, 294-295.	4.9	3
186	Subthreshold Amyloid Predicts Tau Deposition in Aging. <i>Journal of Neuroscience</i> , 2018, 38, 4482-4489.	1.7	101
187	Aberrant Cortical Event-Related Potentials During Associative Learning in Rat Models for Presymptomatic Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 725-740.	1.2	4
188	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
189	Prevalence of preclinical Alzheimer disease. <i>Neurology</i> , 2018, 90, e1682-e1691.	1.5	82
190	Imaging tau and amyloid- $\beta$ proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
191	Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 582.	4.5	285
192	Population Neuroscience. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 1-9.	0.6	32
193	Altered structural network organization in cognitively normal individuals with amyloid pathology. <i>Neurobiology of Aging</i> , 2018, 64, 15-24.	1.5	30
194	Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 693-702.	1.2	30
195	Imaging $A\beta$ and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	1.1	14
196	Quantum dots-based sandwich immunoassay for sensitive detection of Alzheimer's disease-related $A\beta$ 1-42. <i>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</i> , 2018, 201, 82-87.	2.0	32
197	Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. <i>JAMA Neurology</i> , 2018, 75, 970.	4.5	116
198	Amyloid- $\beta$ "a reflection of risk or a preclinical marker?". <i>Nature Reviews Neurology</i> , 2018, 14, 319-320.	4.9	7
199	Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. <i>Neurology</i> , 2018, 90, e1920-e1928.	1.5	36
200	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S647-S657.	1.2	10

#	ARTICLE	IF	CITATIONS
201	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
202	Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the prodementia phase of Alzheimer's disease: Implications for clinical trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 161-171.	1.2	36
203	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. <i>Cerebral Cortex</i> , 2018, 28, 3638-3649.	1.6	29
204	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
205	Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. <i>Pharmacological Research</i> , 2018, 129, 216-226.	3.1	56
206	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
207	Amyloid $\beta$ Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88.	4.5	33
208	Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 140-151.	1.5	30
209	Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1213-1221.	1.2	11
210	Amyloid, tau, pathogen infection and antimicrobial protection in Alzheimer's disease – conformist, nonconformist, and realistic prospects for AD pathogenesis. <i>Translational Neurodegeneration</i> , 2018, 7, 34.	3.6	77
211	The impact of amyloid- $\beta$ and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
212	Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers. <i>Brain</i> , 2018, 141, 3233-3248.	3.7	24
213	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
214	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , 2018, 84, 648-658.	2.8	230
215	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
216	Widespread distribution of tauopathy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 72, 177-185.	1.5	42
217	Exceptional brain aging without Alzheimer's disease: triggers, accelerators, and the net sum game. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 53.	3.0	16
218	Relationship Between Amyloid- $\beta$ Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1313-1325.	1.2	19

#	ARTICLE	IF	CITATIONS
219	Amyloid Accumulation and Cognitive Decline in Clinically Normal Older Individuals: Implications for Aging and Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S633-S646.	1.2	52
220	Effects of Mediterranean Diet on Endothelial Function. , 2018, , 363-389.		1
221	Imaging Translocator Protein as a Biomarker of Neuroinflammation in Dementia. <i>Advances in Pharmacology</i> , 2018, 82, 163-185.	1.2	32
222	A new era for dementia epidemiology: Alzheimer's disease, hardening of arteries, or just old age?. <i>European Journal of Epidemiology</i> , 2018, 33, 613-616.	2.5	5
223	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
224	Ocular Biomarkers of Alzheimer's Disease: The Role of Anterior Eye and Potential Future Directions. , 2018, 59, 3554.		22
225	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	3.0	34
226	18F-FDG PET for Prediction of Conversion to Alzheimer's Disease Dementia in People with Mild Cognitive Impairment: An Updated Systematic Review of Test Accuracy. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1175-1194.	1.2	36
227	Big Data and Dementia: Charting the Route Ahead for Research, Ethics, and Policy. <i>Frontiers in Medicine</i> , 2018, 5, 13.	1.2	51
228	Amyloid- $\beta^2$ , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 193.	1.7	16
229	An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 275.	1.4	38
230	Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer's Disease. <i>Geriatrics (Switzerland)</i> , 2018, 3, 23.	0.6	6
231	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 889-897.	1.2	9
232	Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 16.	3.0	57
233	Association between cognitive function and parameters of echocardiography and coronary artery angiography. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 225-230.	0.3	3
234	Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid- $\beta^2$ and Tau Pathologies. <i>Frontiers in Neurology</i> , 2018, 9, 549.	1.1	86
235	Preclinical Alzheimer's Disease: Implications for Refinement of the Concept. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S213-S227.	1.2	8
236	Using Neuropsychological Process Scores to Identify Subtle Cognitive Decline and Predict Progression to Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 195-204.	1.2	67

#	ARTICLE	IF	CITATIONS
237	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	4.5	102
238	Estimates of age-related memory decline are inflated by unrecognized Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 70, 170-179.	1.5	14
239	High-precision plasma $\beta$ -amyloid 42/40 predicts current and future brain amyloidosis. <i>Neurology</i> , 2019, 93, e1647-e1659.	1.5	514
240	Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. <i>Alzheimer's and Dementia</i> , 2019, 15, 1208-1217.	0.4	45
241	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.5	96
242	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
243	Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging. <i>Annals of Neurology</i> , 2019, 86, 866-877.	2.8	40
244	Peripheral Neuropathy Research Registry: A prospective cohort. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 39-47.	1.4	10
245	Resting State Networks in the TgF344-AD Rat Model of Alzheimer's Disease Are Altered From Early Stages. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 213.	1.7	16
246	History and progress of hypotheses and clinical trials for Alzheimer's disease. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 29.	7.1	370
247	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. <i>Brain Sciences</i> , 2019, 9, 213.	1.1	15
248	Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2952-2961.	1.8	20
249	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 63-106.	0.9	10
250	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	1.8	34
251	Plasma lipocalin-2 levels in the preclinical stage of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 646-653.	1.2	22
252	Elevated tau PET signal depends on abnormal amyloid levels and is uncommon in unimpaired individuals. <i>Brain</i> , 2019, 142, 2903-2904.	3.7	2
253	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	13.5	1,675
254	Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. <i>Alzheimer's and Dementia</i> , 2019, 15, 1392-1401.	0.4	35

#	ARTICLE	IF	CITATIONS
255	Towards Establishing Age-Related Cortical Plasticity on the Basis of Somatosensation. <i>Neuroscience</i> , 2019, 404, 407-412.	1.1	5
256	Manual Acupuncture Regulates Behavior and Cerebral Blood Flow in the SAMP8 Mouse Model of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 37.	1.4	40
257	Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [18F] FDG a specific biomarker in these patients?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1796-1805.	3.3	14
258	EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. <i>Brain</i> , 2019, 142, 2096-2112.	3.7	131
259	Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 323-341.	1.2	146
260	Higher Body Mass Index Is Associated with Lower Cortical Amyloid- $\beta^2$ Burden in Cognitively Normal Individuals in Late-Life. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 817-827.	1.2	23
261	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. <i>Alzheimer's and Dementia</i> , 2019, 15, 888-898.	0.4	290
262	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
263	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2019, 18, 519-520.	4.9	0
264	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
265	Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 27.	3.0	82
266	An <i>UNC5C</i> Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1161-1170.	1.2	5
267	ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. <i>Neurology</i> , 2019, 92, e1567-e1579.	1.5	73
268	Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101767.	1.4	41
269	The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals. <i>Neurology</i> , 2019, 92, 643-644.	1.5	12
270	Amyloid $\beta^{242}$ and Total Tau Levels in Cerebrospinal Fluid Associate with Survival in an 85-Year-Old Population-Based Cohort Followed until Death. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 114-124.	0.7	3
271	Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1549-1559.	1.2	9
272	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	1.5	23



#	ARTICLE	IF	CITATIONS
273	Parafoveal vessel loss and correlation between peripapillary vessel density and cognitive performance in amnesic mild cognitive impairment and early Alzheimer's Disease on optical coherence tomography angiography. <i>PLoS ONE</i> , 2019, 14, e0214685.	1.1	81
274	Distinct patterns of default mode and executive control network circuitry contribute to present and future executive function in older adults. <i>NeuroImage</i> , 2019, 195, 320-332.	2.1	38
275	The Importance of the Validation of M/EEG With Current Biomarkers in Alzheimer's Disease. <i>Frontiers in Human Neuroscience</i> , 2019, 13, 17.	1.0	48
276	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.5	194
277	Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 15-20.	0.6	11
278	Redox proteomics and amyloid $\beta$ peptide: insights into Alzheimer disease. <i>Journal of Neurochemistry</i> , 2019, 151, 459-487.	2.1	80
279	Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2031-2039.	1.8	10
280	Patterns of Grey Matter Atrophy at Different Stages of Parkinson's and Alzheimer's Diseases and Relation to Cognition. <i>Brain Topography</i> , 2019, 32, 142-160.	0.8	36
281	Retinol Binding Protein 4 Levels Are Not Altered in Preclinical Alzheimer's Disease and Not Associated with Cognitive Decline or Incident Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 257-263.	1.2	11
282	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 3-17.	1.0	82
283	A critical appraisal of amyloid- $\beta$ -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
284	Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive Impairment. <i>JAMA Neurology</i> , 2019, 76, 187.	4.5	66
285	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 7.	3.0	87
286	Complement protein levels in plasma astrocyte-derived exosomes are abnormal in conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 61-66.	1.2	70
287	Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease. <i>Annual Review of Public Health</i> , 2019, 40, 65-84.	7.6	94
288	In Brief Neuropsychological Assessment, Amnesic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 715-723.	1.2	5
289	Predicting Progression to Mild Cognitive Impairment. <i>Annals of Neurology</i> , 2019, 85, 155-160.	2.8	32
290	A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study. <i>Journal of Applied Gerontology</i> , 2019, 38, 277-289.	1.0	29

#	ARTICLE	IF	CITATIONS
291	Education as a Moderator of the Relationship Between Episodic Memory and Amyloid Load in Normal Aging. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1820-1826.	1.7	17
292	Application of an amyloid and tau classification system in subcortical vascular cognitive impairment patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 292-303.	3.3	15
293	Differences in Driving Outcomes Among Cognitively Normal African American and Caucasian Older Adults. <i>Journal of Racial and Ethnic Health Disparities</i> , 2020, 7, 269-280.	1.8	4
294	Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. <i>Neurology</i> , 2020, 94, e397-e406.	1.5	93
295	Waist Circumference and Domain-Specific Cognitive Function Among Non-Demented Japanese Older Adults Stratified by Sex: Results from the Takashima Cognition Study. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 887-896.	1.2	8
296	Neuroimaging of Diseases Causing Dementia. <i>Neurologic Clinics</i> , 2020, 38, 65-94.	0.8	9
297	Education does not protect cognitive function from brain pathology in the ADNI 2 cohort. <i>Neurobiology of Aging</i> , 2020, 90, 147-149.	1.5	8
298	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.4	55
299	Medial temporal lobe white matter pathway variability is associated with individual differences in episodic memory in cognitively normal older adults. <i>Neurobiology of Aging</i> , 2020, 87, 78-88.	1.5	8
300	Non-linear Relationship Between Plasma Amyloid- $\beta$ 40 Level and Cognitive Decline in a Cognitively Normal Population. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 557005.	1.7	3
301	Association of Cigarette Smoking With Cerebrospinal Fluid Biomarkers of Neurodegeneration, Neuroinflammation, and Oxidation. <i>JAMA Network Open</i> , 2020, 3, e2018777.	2.8	35
302	Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12104.	1.2	27
303	Identifying subtypes of mild cognitive impairment from healthy aging based on multiple cortical features combined with volumetric measurements of the hippocampal subfields. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 1477-1489.	1.1	15
304	Anti-amyloid- $\beta$ protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	1.0	57
305	The Validation of Multifactor Model of Plasma A $\beta$ 242 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 212.	1.7	18
306	It's complicated: The relationship between sleep and Alzheimer's disease in humans. <i>Neurobiology of Disease</i> , 2020, 144, 105031.	2.1	61
307	Association of midlife vascular risk and AD biomarkers with subsequent cognitive decline. <i>Neurology</i> , 2020, 95, e3093-e3103.	1.5	22
308	Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 96, 233-245.	1.5	20

#	ARTICLE	IF	CITATIONS
309	Sequence of Alzheimer disease biomarker changes in cognitively normal adults. <i>Neurology</i> , 2020, 95, e3104-e3116.	1.5	35
310	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. <i>Journal of Personalized Medicine</i> , 2020, 10, 116.	1.1	26
311	Revisiting the Amyloid Cascade Hypothesis: From Anti-A $\beta$ Therapeutics to Auspicious New Ways for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5858.	1.8	79
312	Distinct Brain Functional Impairment Patterns Between Suspected Non-Alzheimer Disease Pathophysiology and Alzheimer's Disease: A Study Combining Static and Dynamic Functional Magnetic Resonance Imaging. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 550664.	1.7	14
313	Morphometric Changes to Corneal Dendritic Cells in Individuals With Mild Cognitive Impairment. <i>Frontiers in Neuroscience</i> , 2020, 14, 556137.	1.4	20
314	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
315	Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 261-274.	1.2	25
316	Depression is Associated with Tau and Not Amyloid Positron Emission Tomography in Cognitively Normal Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1045-1055.	1.2	52
317	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 26.	3.0	138
318	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local $\beta$ -amyloid, Tau, and APOE4. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 46.	1.7	21
319	Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1119-1129.	1.2	14
320	Impact of urban environmental exposures on cognitive performance and brain structure of healthy individuals at risk for Alzheimer's dementia. <i>Environment International</i> , 2020, 138, 105546.	4.8	69
321	Profile of Pathogenic Proteins and MicroRNAs in Plasma-derived Extracellular Vesicles in Alzheimer's Disease: A Pilot Study. <i>Neuroscience</i> , 2020, 432, 240-246.	1.1	36
322	Spatial navigation ability predicts progression of dementia symptomatology. <i>Alzheimer's and Dementia</i> , 2020, 16, 491-500.	0.4	31
323	Clinical trials of new drugs for Alzheimer disease. <i>Journal of Biomedical Science</i> , 2020, 27, 18.	2.6	453
324	Types and sources of medical and other related data. , 2020, , 19-65.		6
325	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-19.	1.9	40
326	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	4.5	182

#	ARTICLE	IF	CITATIONS
327	Association of <i>Klotho</i> -VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry <i>APOE4</i> . <i>JAMA Neurology</i> , 2020, 77, 849.	4.5	69
328	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	5.8	252
329	Prevalence of the Preclinical Stages of Alzheimer's Disease in Cognitively Intact Older Adults: The CABLE Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 483-492.	1.2	1
330	Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS. <i>Medical Hypotheses</i> , 2020, 141, 109736.	0.8	13
331	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
332	Grey zone amyloid burden affects memory function: the SCIENCE project. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 747-756.	3.3	5
333	High-specificity antibodies and detection methods for quantifying phosphorylated tau from clinical samples. <i>Antibody Therapeutics</i> , 2021, 4, 34-44.	1.2	7
334	The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease. <i>Journal of Central Nervous System Disease</i> , 2021, 13, 117957352110291.	0.7	64
335	Fractal motor activity regulation and sex differences in preclinical Alzheimer's disease pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12211.	1.2	12
336	Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer's Disease: Results from the Gothenburg H70 Birth Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 225-235.	1.2	4
337	Amyloid $\beta$ , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9
338	Functional connectivity in aging. , 2021, , 37-51.		3
339	Structural Network Efficiency Predicts Resilience to Cognitive Decline in Elderly at Risk for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 637002.	1.7	10
340	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 3363-3373.	1.6	4
341	Cerebrospinal fluid heart fatty acid-binding protein as a predictive biomarker of neurodegeneration in Alzheimer's disease. <i>Brain Science Advances</i> , 2021, 7, 44-55.	0.3	1
342	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI) Tj ETQq1 1,0.784314,rgBT /Ove 2.7		
343	Early identification of Alzheimer's disease in mouse models: Application of deep neural network algorithm to cognitive behavioral parameters. <i>IScience</i> , 2021, 24, 102198.	1.9	14
344	Biomarqueurs du liquide c�rebrospinal. <i>Pratique Neurologique - FMC</i> , 2021, 12, 165-179.	0.1	1

#	ARTICLE	IF	CITATIONS
345	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
346	Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults. <i>Psychological Science</i> , 2021, 32, 849-860.	1.8	8
347	Pathological drivers of neurodegeneration in suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 100.	3.0	13
348	Network dysfunction in cognitively normal APOE $\epsilon$ 4 carriers is related to subclinical tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 116-126.	0.4	7
349	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. <i>Current Neuropharmacology</i> , 2022, 20, 713-737.	1.4	8
350	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. <i>Journal of Internal Medicine</i> , 2021, 290, 583-601.	2.7	54
351	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , 2021, 16, 49.	4.4	43
352	12-year prediction of mild cognitive impairment aided by Alzheimer's brain signatures at mean age 56. <i>Brain Communications</i> , 2021, 3, fcab167.	1.5	7
353	The Association Between Plasma $\tau$ -Synuclein ( $\tau$ -syn) Protein, Urinary Alzheimer-Associated Neuronal Thread Protein (AD7c-NTP), and Apolipoprotein Epsilon 4 (ApoE $\epsilon$ 4) Alleles and Cognitive Decline in 60 Patients with Alzheimer's Disease Compared with 28 Age-Matched Normal Individuals. <i>Medical Science Monitor</i> , 2021, 27, e932998.	0.5	4
354	Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort. <i>Frontiers in Big Data</i> , 2021, 4, 676168.	1.8	5
355	Time to Diagnosis in Young Onset Alzheimer's Disease: A Population-Based Study from Central Norway. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 965-974.	1.2	18
356	Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer's disease: Limitations, and current and future perspectives. <i>Journal of Trace Elements in Medicine and Biology</i> , 2021, 67, 126779.	1.5	60
357	Operational Determination of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using Sum of Boxes of the Clinical Dementia Rating Scale. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 705782.	1.7	9
358	Falls: a marker of preclinical Alzheimer disease: a cohort study protocol. <i>BMJ Open</i> , 2021, 11, e050820.	0.8	8
359	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 153.	3.0	3
360	Diagnostic biomarkers in Alzheimer's disease. <i>Biomarkers in Neuropsychiatry</i> , 2021, 5, 100041.	0.7	12
361	Autobiographical Memory Fluency Reductions in Cognitively Unimpaired Middle-Aged and Older Adults at Increased Risk for Alzheimer's Disease Dementia. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 905-915.	1.2	6
362	Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12198.	1.2	4

#	ARTICLE	IF	CITATIONS
363	Demenz, Wahn und bloÃŸes Altsein: Regeln und Besonderheiten der SchuldÃfhigkeitsbegutachtung Ãlterer StraftÃter. , 2015, , 167-192.		2
364	Amyloid-Î² and Tau at theÃCrossroads of Alzheimerâ€™s Disease. Advances in Experimental Medicine and Biology, 2019, 1184, 187-203.	0.8	115
365	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. Neurobiology of Aging, 2020, 94, 71-80.	1.5	14
366	Process dissociation analyses of memory changes in healthy aging, preclinical, and very mild Alzheimer disease: Evidence for isolated recollection deficits.. Neuropsychology, 2017, 31, 708-723.	1.0	7
367	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54
370	A Novel Blood-Brain Barrier Co-Culture System for Drug Targeting of Alzheimerâ€™s Disease: Establishment by Using Acitretin as a Model Drug. PLoS ONE, 2014, 9, e91003.	1.1	42
371	Role of Body-Fluid Biomarkers in Alzheimerâ€™s Disease Diagnosis. Diagnostics, 2020, 10, 326.	1.3	12
372	Use of ocular biomarkers as a potential tool for early diagnosis of Alzheimer's disease. Indian Journal of Ophthalmology, 2020, 68, 555.	0.5	21
374	New Frontiers in Alzheimer's Disease Diagnosis. , 0, , .		0
375	A Fate Worse Than Death?: How Biomarkers for Alzheimer's Disease Could Affect End-of-Life Choices. Indiana Health Law Review, 2015, 12, 651.	0.1	1
376	Dementia and Bioethics. Mental Health and Illness Worldwide, 2016, , 1-13.	0.1	0
377	Dementia and Bioethics. Mental Health and Illness Worldwide, 2017, , 141-153.	0.1	0
378	The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimerâ€™s Disease. Neuromethods, 2018, , 249-258.	0.2	2
379	Adequacy of food consumption in elderly Alzheimerâ€™s disease in a community of Southern Brazil: a Cross-sectional study. F1000Research, 0, 7, 671.	0.8	0
382	ROLE OF PATHOGENIC PROTEINS AND CHRONIC INFLAMMATION IN THE OCCURRENCE OF ALZHEIMER'S DISEASE. Eastern Ukrainian Medical Journal, 2020, 8, 475-490.	0.0	0
385	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. Innovations in Clinical Neuroscience, 2017, 14, 22-29.	0.1	34
386	Long-term prognosis and educational determinants of brain network decline in older adult individuals. Nature Aging, 2021, 1, 1053-1067.	5.3	45
387	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nature Reviews Neuroscience, 2022, 23, 53-66.	4.9	203

#	ARTICLE	IF	CITATIONS
388	UPDATE ON PREVENTION TRIALS IN ALZHEIMER'S DISEASE. <i>Journal of Prevention of Alzheimer's Disease</i> , 2014, 1, 1-8.	1.5	3
389	Relationship between Olfactory Identification Test and Cognitive Function in a Community-dwelling Population in Japan. <i>Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology)</i> , 2021, 60, 509-515.	0.0	1
390	CSF markers of AD-related pathology relate specifically to memory impairment in older people with HIV: a pilot study. <i>Journal of NeuroVirology</i> , 2022, 28, 162-167.	1.0	5
391	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, fca026.	1.5	4
392	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	2.7	65
393	Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 2570-2581.	0.4	8
394	A Pathway-Specific Polygenic Risk Score Is Associated with Tau Pathology and Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1745-1754.	1.2	4
395	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
396	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 811146.	1.7	5
397	Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time. <i>European Journal of Neurology</i> , 2022, 29, 1922-1929.	1.7	4
398	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2022, 374, 109581.	1.3	2
399	Alzheimer disease in African American individuals: increased incidence or not enough data?. <i>Nature Reviews Neurology</i> , 2022, 18, 56-62.	4.9	51
400	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
401	Blood-Based Biomarkers for Alzheimer's Disease Diagnosis and Progression: An Overview. <i>Cells</i> , 2022, 11, 1367.	1.8	31
422	PET Imaging of Amyloid and Tau in Alzheimer's Disease. , 2022, , 307-323.		2
423	Commentary: Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 895398.	1.7	0
425	Alzheimer's Disease (AD): Risks, Treatments, Prevention, and Future Implementations. <i>Advances in Alzheimer's Disease</i> , 2022, 11, 11-21.	0.3	3
426	Incremental diagnostic value of 18F-Fluorometamol PET in differential diagnoses of Alzheimer's Disease-related neurodegenerative diseases from an unselected memory clinic cohort. <i>Scientific Reports</i> , 2022, 12, .	1.6	3

#	ARTICLE	IF	CITATIONS
427	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
428	Alzheimer Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 648-675.	0.4	6
429	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. <i>Neuroepidemiology</i> , 2022, 56, 309-318.	1.1	13
430	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 759-771.	1.9	6
431	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. <i>Brain</i> , 2022, 145, 4506-4518.	3.7	15
432	Amyloid- $\beta^2$ levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. <i>Brain</i> , 2022, 145, 4032-4041.	3.7	12
433	Associations Between Sub-Threshold Amyloid- $\beta^2$ Deposition, Cortical Volume, and Cognitive Function Modulated by APOE $\epsilon^4$ Carrier Status in Cognitively Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	1.2	0
434	Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. <i>Clinical Neurophysiology</i> , 2022, 142, 190-198.	0.7	2
435	Progression of Subjective Cognitive Decline to MCI or Dementia in Relation to Biomarkers for Alzheimer Disease. <i>Neurology</i> , 2022, 99, .	1.5	13
436	Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. <i>Brain</i> , 2022, 145, 4459-4473.	3.7	15
437	Angiotensin Receptor Blockers Are Associated With a Lower Risk of Progression From Mild Cognitive Impairment to Dementia. <i>Hypertension</i> , 2022, 79, 2159-2169.	1.3	17
438	Optimized, personalized, and digitalized: protocol for a fully-remote precision clinical trial of mindfulness training for depressed older adults using smartphone technology Abstract (Preprint). <i>JMIR Research Protocols</i> , 0, , .	0.5	0
439	Circular RNAs in Alzheimer's Disease: A New Perspective of Diagnostic and Therapeutic Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 1335-1354.	0.8	7
440	How can secondary dementia prevention trials of Alzheimer's disease be clinically meaningful?. <i>Alzheimer's and Dementia</i> , 2023, 19, 1073-1085.	0.4	1
441	A genetically modified minipig model for Alzheimer's disease with SORL1 haploinsufficiency. <i>Cell Reports Medicine</i> , 2022, 3, 100740.	3.3	15
442	Comparison of plasma and CSF biomarkers in predicting cognitive decline. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1739-1751.	1.7	20
443	CSF Alzheimer Disease Biomarkers. <i>Neurology</i> , 2022, 99, .	1.5	9
444	A Framework for Early Recognition of Alzheimer's Disease Using Machine Learning Approaches. <i>Lecture Notes in Networks and Systems</i> , 2023, , 1-13.	0.5	0



#	ARTICLE	IF	CITATIONS
445	Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	3
446	Sexually Dimorphic Association of Circulating Plasminogen Activator Inhibitor-1 Levels and Body Mass Index with Cerebrospinal Fluid Biomarkers of Alzheimer's Pathology in Preclinical Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	1
447	Role of monomeric amyloid- $\beta^2$ in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies. <i>Pharmacological Research</i> , 2023, 187, 106631.	3.1	22
448	Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 2923-2932.	0.4	1
449	Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 291-303.	1.2	1
450	A Note on Changing Approach to Diagnosis of Alzheimer's Disease. <i>European Medical Journal Neurology</i> , 0, , 87-94.	0.0	1
451	Update on Alzheimer's Disease. <i>European Medical Journal Neurology</i> , 0, , 82-90.	0.0	1
452	Characteristics of Subjective Cognitive Decline Associated with Alzheimer's Disease Amyloid Pathology: Findings from The CABLE Study. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 581-590.	1.2	1
456	Detection and treatment of Alzheimer's disease in its preclinical stage. <i>Nature Aging</i> , 2023, 3, 520-531.	5.3	12
469	Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums. <i>Nature Reviews Neurology</i> , 2024, 20, 162-182.	4.9	0